This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Oxaprozin

Dosage Form; Route: Tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in vivo
   Strength: 600 mg
   Subjects: Healthy males and females, general population
   Additional comments: Females should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in vivo
   Strength: 600 mg
   Subjects: Healthy males and females, general population
   Additional comments: See comments above.

Analytes to measure (in appropriate biological fluid): Oxaprozin in plasma

Bioequivalence based on (90% CI): Oxaprozin

Waiver request of in vivo testing: Not Applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).

Note that the Reference Listed Drug, DAYPRO 600 mg caplet, is a capsule-shaped and scored tablet. For additional information related to scored tablets, refer to the guidance on "Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation" issued in March 2013 at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269921.pdf.